Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh

NCT01122771 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

602

Enrollment

OTHER

Sponsor class

Conditions

Visceral Leishmaniasis

Interventions

DRUG: Liposomal amphotericin B
DRUG: liposomal amphotericin B + miltefosine
DRUG: liposomal amphotericin B + paromomycin
DRUG: Miltefosine + Paromomycin

Sponsor

Drugs for Neglected Diseases

Collaborators

[object Object]
[object Object]